Literature DB >> 8290271

Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene.

C A Purdie1, D J Harrison, A Peter, L Dobbie, S White, S E Howie, D M Salter, C C Bird, A H Wyllie, M L Hooper.   

Abstract

In human tumourigenesis the tumour suppressor gene most commonly affected by mutation, inactivation or allele loss is p53. Loss of p53 function is associated both with failure to maintain a normal diploid status and inability to delete cells by apoptosis following DNA damage. To investigate further the role of p53 we have generated mice carrying a large deletion within the gene. All animals homozygous for this deletion develop spontaneous tumours, predominantly lymphomas, by the age of 6 months. 10% of heterozygotes develop a range of neoplasms, with a lower predisposition towards lymphoma, by 9 months. Both tumour incidence and spectrum in heterozygotes differ from those previously reported in another p53 mutant stock, suggesting either difference in exposure to carcinogens between the two stocks, or a role for modulating genes within different genetic backgrounds. Tumours showed frequent loss of diploid status, and the majority of those arising in heterozygotes showed loss of the wild type allele. These findings are consistent with the concept that p53 acts as a tumour suppressor by preventing the propagation of DNA damage to daughter cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8290271

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  77 in total

1.  Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.

Authors:  K M La Perle; S M Jhiang; C C Capen
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Analysis of fused maxillary incisor dentition in p53-deficient exencephalic mice.

Authors:  M H Kaufman; D B Kaufman; R M Brune; M Stark; J F Armstrong; A R Clarke
Journal:  J Anat       Date:  1997-07       Impact factor: 2.610

3.  Regulation of ES cell differentiation by functional and conformational modulation of p53.

Authors:  K Sabapathy; M Klemm; R Jaenisch; E F Wagner
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

4.  Altered mammary gland development in the p53+/m mouse, a model of accelerated aging.

Authors:  Catherine E Gatza; Melissa Dumble; Frances Kittrell; David G Edwards; Robert K Dearth; Adrian V Lee; Jianming Xu; Daniel Medina; Lawrence A Donehower
Journal:  Dev Biol       Date:  2007-10-12       Impact factor: 3.582

5.  The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability.

Authors:  Michael Overholtzer; Pulivarthi H Rao; Reyna Favis; Xin-Yan Lu; Michael B Elowitz; Francis Barany; Marc Ladanyi; Richard Gorlick; Arnold J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

6.  Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium.

Authors:  S Fujii; T Fujimori; H Kawamata; J Takeda; K Kitajima; F Omotehara; T Kaihara; T Kusaka; K Ichikawa; Y Ohkura; Y Ono; J Imura; S Yamaoka; C Sakamoto; Y Ueda; T Chiba
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

7.  Guilty as CHARGED: p53's expanding role in disease.

Authors:  Jeanine L Van Nostrand; Laura D Attardi
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 8.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

Review 9.  Lessons from the p53 mutant mouse.

Authors:  T Jacks
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

10.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.